New hope for tough cancers: first test of experimental drug begins

NCT ID NCT05007782

Summary

This is a first-in-human study to test the safety and find the right dose of a new immunotherapy drug called denikitug. It is being tested alone and in combination with another immunotherapy drug in adults with advanced solid tumors that have stopped responding to available treatments. The main goals are to see how safe the drug is and if it shows any early signs of helping to control the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beth Israel Deaconess Medical Center

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Chang Gung Medical Foundation Linkou Chang Gung Memorial Hospital

    RECRUITING

    Taoyuan, 33308, Taiwan

  • Changhua Christian Hospital

    RECRUITING

    Changhua, 500, Taiwan

  • Chi Mei Hospital, Liouying

    RECRUITING

    Tainan, 73657, Taiwan

  • Chris O'Brien Lifehouse

    RECRUITING

    Camperdown, New South Wales, 2050, Australia

  • Clinica Universidad de Navarra

    RECRUITING

    Pamplona, 31008, Spain

  • Hospital Universitari Vall d´Hebrón

    RECRUITING

    Barcelona, 08035, Spain

  • Hospital Universitario 12 de Octubre

    RECRUITING

    Madrid, 28041, Spain

  • Hospital Universitario Quironsalud Madrid

    RECRUITING

    Madrid, 28223, Spain

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

  • MD Anderson Cancer Center

    RECRUITING

    Madrid, 28033, Spain

  • Monash Medical Centre

    RECRUITING

    Clayton, Victoria, 3168, Australia

  • NEXT Oncology

    RECRUITING

    San Antonio, Texas, 78229, United States

  • National Taiwan University Cancer Center (NTUCC)

    RECRUITING

    Taipei, 100229, Taiwan

  • National Taiwan University Hospital

    RECRUITING

    Taipei, 100, Taiwan

  • Peter MacCallum Cancer Centre

    RECRUITING

    Melbourne, Victoria, 3000, Australia

  • Sarah Cannon Research Institute at Mary Crowley

    RECRUITING

    Dallas, Texas, 75230, United States

  • Smilow Cancer Center

    COMPLETED

    New Haven, Connecticut, 06510, United States

  • Stanford Cancer Center

    RECRUITING

    Palo Alto, California, 94305, United States

  • Taipei Tzu Chi General Hospital

    WITHDRAWN

    Taipei, 110, Taiwan

  • Taipei Veterans General Hospital

    RECRUITING

    Taipei, 11217, Taiwan

  • Tennessee Oncology, PLLC

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • University Health Network, Princess Margaret Cancer Centre

    RECRUITING

    Toronto, M5G 2M9, Canada

  • University of California San Diego

    RECRUITING

    La Jolla, California, 92093, United States

  • University of Texas Southwestern Medical Center

    RECRUITING

    Dallas, Texas, 39090, United States

  • University of Wisconsin Clinical Sciences Center

    RECRUITING

    Madison, Wisconsin, 53705, United States

Conditions

Explore the condition pages connected to this study.